'Alzheimer's disease': More data, but are we any more informed?

Current Opinion in Psychiatry

Volumn 18, Issue 6, 2005, Pages 615-620

  For̈rstl, Hans ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Alzheimer; Cerebral multimorbidity; Hashimoto encephalitis; Mild cognitive impairment; Pseudo Alzheimer

Indexed keywords

ALPHA TOCOPHEROL; DONEPEZIL; N ACETYLASPARTIC ACID; RALOXIFENE; RIVASTIGMINE; ROFECOXIB;

ALZHEIMER DISEASE; BRAIN DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; HASHIMOTO DISEASE; HUMAN; PARANEOPLASTIC NEUROPATHY; PARKINSON DISEASE; PSYCHOMOTOR DISORDER; REVIEW; TAUOPATHY;

EID: 27644519162     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yco.0000185717.57117.08     Document Type: Review

References (69)

1. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. Neurosci Lett 2004; 370:127-129. This documents that cholinesterase inhibition is not the treatment for 'Alzheimer's disease', but for several conditions characterized by cholinergic deficits. Certain interested parties may try to sell this study in order to propagate a concept of 'Parkinson disease dementia', etc.
2. Aarsland D, Ballard CG, Halliday G. Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? J Geriatr Psychiatry Neural 2004; 17:137-145.
3. Guo L, Itaya M, Takanashi M, et al. Relationship between Parkinson disease with dementia and dementia with Lewy bodies. Dement Geriatr Cogn Disord 2005; 19:57-60.
4. Mori H. Pathological substrate of dementia in Parkinson's disease: its relation to DLB and DLBD. Parkinsonism Relat Disord 2005 [Epub ahead of print].
5. Kumar R, Dear KB, Christensen H, et al. Prevalence of mild cognitive impairment in 60- to 64-year-old community-dwelling individuals: the Personality and Total Health through Life 60+ Study. Dement Geriatr Cogn Disord 2005; 19:67-74.
6. Jungwirth S, Weissgram S, Zehetmayer S, et al. VITA: subtypes of mild cognitive impairment in a community-based cohort at the age of 75 years, Int J Geriatr Psychiatry 2005; 20 (5):452-458. The authors offer a meticulous description of the highly prevalent and varied mild cognitive disturbances in 75-76-year-olds.
7. de Jager CA, Budge MM. Stability and predictability of the classification of mild cognitive impairment as assessed by episodic memory test performance over time. Neurocase 2005; 11:72-79.
8. Ivanoiu A, Adam S, Van der Linden M, et al. Memory evaluation with a new cued recall test in patients with mild cognitive impairment and Alzheimer's disease. J Neurol 2005; 252:47-55.
9. Shankle WR, Romney AK, Hara J, et al. Methods to improve the detection of mild cognitive impairment. Proc Natl Acad Sci U S A 2005; 102:4919-4924.
10. Borson S, Scanlan JM, Watanabe J, et al. Simplifying detection of cognitive impairment: comparison of the mini-cog and mini-mental state examination in a multiethnic sample. J Am Geriatr Soc 2005; 53:871-874.
11. Molloy DW, Standish TI, Lewis DL. Screening for mild cognitive impairment: comparing the SMMSE and the ABCS. Can J Psychiatry 2005; 50: 52-58.
12. Tornatore JB, Hill E, Laboff JA, McGann ME. Self-administered screening for mild cognitive impairment: initial validation of a computerized test battery. J Neuropsychiatry Clin Neurosci 2005; 17:98-105.
13. Levinoff EJ, Saumier D, Chertkow H. Focused attention deficits in patients with Alzheimer's disease and mild cognitive impairment. Brain Cogn 2005; 57:127-130.
14. Jorm AF, Masaki KH, Petrovitch H, et al. Cognitive deficits 3 to 6 years before dementia onset in a population sample: the Honolulu-Asia aging study. J Am Geriatr Soc 2005; 53:452-455. An important study on the very early and ambiguous subjective symptoms of incipient memory deficits.
15. Lopez OL, Becker JT, Sweet RA. Non-cognitive symptoms in mild cognitive impairment subjects. Neurocase 2005; 11:65-71.
16. Tuokko H, Morris C, Ebert P. Mild cognitive impairment and everyday functioning in older adults. Neurocase 2005; 11:40-47. This study shatters the notion that MCI was not characterized by relevant impairment of activities of daily living.
17. Kazui H, Matsuda A, Hirono N, et al. Everyday memory impairment of patients with mild cognitive impairment. Dement Geriatr Cogn Disord 2005; 19:331-337. The authors explain the relationship between an impairment of activities of daily living and certain relevant factors of MCI, which are not typically examined.
18. Kalbe E, Salmon E, Perani D, et al. Anosognosia in very mild Alzheimer's disease but not in mild cognitive impairment. Dement Geriatr Cogn Disord 2005; 19:349-356. Retained insight is associated with distress in MCI.
19. Von Dras DD, Powless MR, Olson AK, et al. Differential effects of everyday stress on the episodic memory test performances of young, mid-life, and older adults. Aging Ment Health 2005; 9:60-70.
20. Lieberman HR, Bathalon GP, Falco CM, et al. Severe decrements in cognition function and mood induced by sleep loss, heat, dehydration, and under-nutrition during simulated combat. Biol Psychiatry 2005; 57:422-429.
21. Gais S, Born J. Declarative memory consolidation: mechanisms acting during human sleep. Learn Mem 2004; 11:679-685. See Ref. [22.
22. Gais S, Born J. Low acetylcholine during slow-wave sleep is critical for declarative memory consolidation. Proc Natl Acad Sci U S A 2004; 101: 2140-2144. Both studies [21] and [22] prepare the ground for a better understanding of nocturnal learning and its disruption due to disturbed sleep. This research needs to be expanded and applied to the problems of demented patients and their relatives.
23. Wolf H, Hensel A, Kruggel F, et al. Structural correlates of mild cognitive impairment. Neurobiol Aging 2004; 25:913-924.
24. Stoub TR, Bulgakova M, Leurgans S, et al. MRI predictors of risk of incident Alzheimer disease: a longitudinal study. Neurology 2005; 64:1520-1524.
25. Kantarci K, Petersen RC, Boeve BF, et al. DWI predicts future progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology 2005; 64:902-904.
26. Pennanen C, Testa C, Laakso MP, et al. A voxel based morphometry study on mild cognitive impairment. J Neural Neurosurg Psychiatry 2005; 76:11-14.
27. Johnson NA, Jahng GH, Weiner MW, et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 2005; 234:851-859.
28. Chetelat G, Eustache F, Viader F, et al. FDG-PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 2005; 11:14-25.
29. Falini A, Bozzali M, Magnani G, et al. A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment. Neuroimage 2005 [Epub ahead of print].
30. Modrego PJ, Fayed N, Pina MA. Conversion from mild cognitive impairment to probable Alzheimer's disease predicted by brain magnetic resonance spectroscopy. Am J Psychiatry 2005; 162:667-675.
31. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med 2005 [Epub ahead of print].
32. Seltzer B, Zolnouni P, Nunez M, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. Arch Neural 2004; 61:1852-1856.
33. Hashimoto M, Kazui H, Matsumoto K, et al. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am J Psychiatry 2005; 162:676-682. A promising result indicating a decreased hipppocampal volume loss and a potential neuroprotective effect due to donepezil treatment.
34. Borroni B, Agosti C, Martini G, et al. Cholinesterase inhibitors exert a protective effect on endothelial damage in Alzheimer disease patients. J Neural Sci 2005; 229-230:211-213.
35. Yaffe K, Krueger K, Cummings SR, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry 2005; 162:683-690.
36. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. J Am Med Assoc 2003; 289:2651 -2662.
37. Espeland MA, Rapp SR, Shumaker SA, et al. Women's Health Initiative Memory Study. Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. J Am Med Assoc 2004; 291:2959-2968.
38. Espeland MA, Gu L, Masaki KH, et al. Association between reported alcohol intake and cognition: results from the Women's Health Initiative Memory Study. Am J Epidemiol 2005; 161:228-238.
39. Thai LJ, Ferris SH, Kirby L, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005 [Epub ahead of print].
40. Luijpen MW, Swaab DF, Sergeant JA, et al. Effects of transcutaneous electrical nerve stimulation (TENS) on memory in elderly with mild cognitive impairment. Behav Brain Res 2005; 158:349-357.
41. de Mendonca A, Ribeiro F, Guerreiro M, et al. Clinical significance of subcortical vascular disease in patients with mild cognitive impairment. Stroke 2005 [Epub ahead of print].
42. Galluzzi S, Sheu CF, Zanetti O, Frisoni GB. Distinctive clinical features of mild cognitive impairment with subcortical cerebrovascular disease. J Neurol Sci 2005; 229-230:121-129.
43. Gold G, Kovari E, Herrmann FR, Canuto A, et al. Cognitive consequences of thalamic, basal ganglia, and deep white matter lacunes in brain aging and dementia. Dement Geriatr Cogn Disord 2005; 19:113-119.
44. Honig LS, Kukull W, Mayeux R. Vascular pathologies and cognition in a population-based cohort of elderly people. Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center. J Am Med Assoc 2004; 292:2901-2908.
45. Bennett DA, Schneider JA, Bienias JL, et al. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Dement Geriatr Cogn Disord 2005; 19:196-203. Who would have thought that religious orders would allow us to leave traditional views behind and take a fresh look at the nature of earthly matters? Supreme support for the MRC-CFAS doctrine.
46. Andin U, Gustafson L, Passant U, Brun A. A clinico-pathological study of heart and brain lesions in vascular dementia. J Neurol Sci 2004; 226:13-17. A further authoritative study supporting the prevalence and importance of cerebral multi-morbidity.
47. Fernando MS, Ince PG. Vascular pathologies and cognition in a population-based cohort of elderly people. J Neurol Sci 2004; 226:13-17. Another slice from the landmark study. The MRC-CFAS study defines the standards not only for future clinico-pathological research in the dementia field, but also for our clinical and therapeutic reasoning.
48. deCarli C, Mungas D, Harvey D, et al. Memory impairment, but not cerebrovascular disease, predicts progression of MCI to dementia. Neurology 2004; 63:220-227.
49. Rasquin S, Lodder J, Verhey F. The association between psychiatric and cognitive symptoms after stroke: a prospective study. Dement Geriatr Cogn Disord 2004; 18:138-144.
50. Rasquin SM, Lodder J, Ponds RW, et al. Cognitive functioning after stroke: a one-year follow-up study. J Neurol Neurosurg Psychiatry 2004; 75:1562-1567.
51. Rasquin SM, Lodder J, Visser PJ, et al. Predictive accuracy of MCI subtypes for Alzheimer's disease and vascular dementia in subjects with mild cognitive impairment: a 2-year follow-up study. Neurology 2004; 63:1882-1891.
52. Rasquin SM, Lodder J, Verhey FR. Predictors of reversible mild cognitive impairment after stroke: a 2-year follow-up study. Dement Geriatr Cogn Disord 2005; 19:222-228.
53. Rasquin SM, Verhey FR, van Oostenbrugge RJ, et al. Demographic and CT scan features related to cognitive impairment in the first year after stroke. J Neurol Sci 2005; 229-230:21-25.
54. Solfrizzi V, Panza F, Colacicco AM, et al. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Italian Longitudinal Study on Aging Working Group. Cerebrovasc Dis 2005; 19:309-316.
55. Kuller LH, Lopez OL, Jagust WJ, et al. Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Hypertension 2004; 44:29-34.
56. Korf ES, White LR, Scheltens P, Launer LJ. Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Stroke 2004; 35 (11 Suppl 1):2616-2619. A study which contributes to our understanding of the interactions between midlife morbidity, neurobiology and late cognitive epiphenomena.
57. Dufouil C, Richard F, Fievet N, et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Am J Med 2005; 118:161-167. Interesting, but is it lipid-lowering treatment which lowers the risk of dementia or are other factors of associated health behaviour more important?
58. Pomara N, Willoughby L, Wesnes K, et al. Apolipoprotein E epsilon4 allele and lorazepam effects on memory in high-functioning older adults. Neurology 2004; 63:1181-1186.
59. Huang W, Qiu C, von Strauss E, et al. APOE genotype, family history of dementia, and Alzheimer disease risk: a 6-year follow-up study. Arch Gen Psychiatry 2005; 62:565-573.
60. Silverman JM, Ciresi G, Smith CJ, et al. Variability of familial risk of Alzheimer disease across the late life span. Am J Geriatr Psychiatry 2005; 13:116-123.
61. Xu WL, Qiu CX, Wahlin A, et al. Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Arch Neurol 2004; 61:1930-1934.
62. Kado DM, Karlamangla AS, Huang MH, et al. Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. Arch Gen Psychiatry 2005; 62:209-216.
63. Ances BM, Vitaliani R, Taylor RA, et al. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 2005 [Epub ahead of print]. Not everything that looks like Alzheimer's disease should be treated with anti-dementia drugs. This is an important memento.
64. Doherty CP. Possibly, probably definitely, Hashimoto encephalopathy. J Neurol Sci 2005; 228:3-5.
65. Gunther P, Kopf A. Hashimoto encephalopathy. Psychiatr Prax 2004; 31:310-312.
66. Chong JY, Rowland LP, Utiger RD. Hashimoto encephalopathy: syndrome or myth? Arch Neurol 2003; 60:164-171.
67. Song YM, Seo DW, Chang GY. MR findings in Hashimoto encephalopathy. AJNR American Journal of Neuroradiology 2004; 25:807-808.
68. Hussain NS, Rumbaugh J, Kerr D, et al. Effects of prednisone and plasma exchange on cognitive impairment in Hashimoto encephalopathy. Neurology 2005; 64:165-166.
69. Mahad DJ, Staugaitis S, Ruggieri P, et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis and primary CNS demyelination. J Neurol Sci 2005; 228:3-5.